Literature DB >> 11137041

Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85.

A S Malin1, K Huygen, J Content, M Mackett, L Brandt, P Andersen, S M Smith, H M Dockrell.   

Abstract

There is increasing evidence to implicate a role for CD8(+) T cells in protective immunity against tuberculosis. Recombinant vaccinia (rVV) expressing Mycobacterium tuberculosis (MTB) proteins can be used both as tools to dissect CD8(+) T-cell responses and, in attenuated form, as candidate vaccines capable of inducing a balanced CD4(+)/CD8(+) T-cell response. A panel of rVV was constructed to express four immunodominant secreted proteins of MTB: 85A, 85B and 85C and ESAT-6. A parallel group of rVV was constructed to include the heterologous eukaryotic tissue plasminogen activator (tPA) signal sequence to assess if this would enhance expression and immunogenicity. Clear expression was obtained for 85A, 85B and ESAT-6 and the addition of tPA resulted in N-glycosylation and a 4-10-fold increase in expression. Female C57BL/6 mice were immunised using the rVV-Ag85 constructs, and interleukin-2 and gamma-interferon were assayed using a co-culture of immune splenocytes and recall antigen. There was a marked increase in cytokine production in mice immunised with the tPA-containing constructs. We report the first data demonstrating enhanced immunogenicity of rVV using a tPA signal sequence, which has significant implications for future vaccine design.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137041     DOI: 10.1016/s1286-4579(00)01323-x

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  11 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Authors:  Danilo R Casimiro; Aimin Tang; Helen C Perry; Romnie S Long; Minchun Chen; Gwendolyn J Heidecker; Mary-Ellen Davies; Daniel C Freed; Natasha V Persaud; Sheri Dubey; Jeffrey G Smith; Diane Havlir; Douglas Richman; Michael A Chastain; Adam J Simon; Tong-Ming Fu; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis.

Authors:  M Harboe; A S Malin; H S Dockrell; H G Wiker; G Ulvund; A Holm; M C Jørgensen; P Andersen
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 4.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

5.  Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.

Authors:  Evans L N Taracha; Richard Bishop; Antony J Musoke; Adrian V S Hill; Sarah C Gilbert
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 6.  Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.

Authors:  Samuel M Behar; Joshua S M Woodworth; Ying Wu
Journal:  Expert Rev Vaccines       Date:  2007-06       Impact factor: 5.217

7.  Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis.

Authors:  Neeraj Dhar; Vivek Rao; Anil K Tyagi
Journal:  Med Microbiol Immunol       Date:  2003-08-02       Impact factor: 3.402

8.  Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.

Authors:  Jia Lu; Chun Wang; Zhiguang Zhou; Ying Zhang; Tingting Cao; Chunwei Shi; Zhenhua Chen; Lingxia Chen; Changxue Cai; Xionglin Fan
Journal:  Clin Dev Immunol       Date:  2011-02-27

9.  A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.

Authors:  Elena López-Gil; Gema Lorenzo; Esther Hevia; Belén Borrego; Martin Eiden; Martin Groschup; Sarah C Gilbert; Alejandro Brun
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11

10.  A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis.

Authors:  Peter C L Beverley; Zsolt Ruzsics; Ariann Hey; Claire Hutchings; Simone Boos; Beatrice Bolinger; Emanuele Marchi; Geraldine O'Hara; Paul Klenerman; Ulrich H Koszinowski; Elma Z Tchilian
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.